A comprehensive view of Capsules/Pills/Tablets. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Raymond James: Perrigo's acquisition of HRA Pharma may be overlooked by investors, as HRA is expected to file application for OTC birth control pill by end-2022; in light of Roe v. Wade ruling, potential annual sales of HRA pill could hit US$100M-US$200M
Published: June 27, 2022 by Benzinga Lightning Feed
FDA grants accelerated approval for oral Tafinlar dabrafenib and Mekinist trametinib from Novartis to treat unresectable or metastatic solid tumors with BRAF V600E mutation in adult, pediatric patients; BRAF V600E accounts for 90% of BRAF-mutant cancers
Published: June 27, 2022 by PharmaBiz
Bristol Myers Squibb reports Phase 3 trials show early Zeposia ozanimod oral treatment improved or preserved cognitive function in patients with relapsing multiple sclerosis; MS affects 700,000 people in Europe, 2.5 million people globally
Published: June 27, 2022 by Business Wire
Analysts on Enanta suing Pfizer over Covid pill Paxlovid: SVB Securities says it's unclear whether Enanta is in the right, noting patent dates might not prove who 'invented' technology first; RBC says it could take years for lawsuit to reach conclusion
Published: June 22, 2022 by Investor's Business Daily
Enanta files suit in US District Court against Pfizer seeking damages for copyright infringement related to Paxlovid nirmatrelvir, ritonavir tablets; Enanta applied for a patent for a coronavirus protease inhibitor in 2020 and received patent this month
Published: June 22, 2022 by Business Wire

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count